A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung Interventions: Drug: Tislelizumab; Drug: Concurrent chemoradiotherapy (cCRT); Other: Placebo Sponsors: Celgene; BeiGene Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Lung Cancer | Non-Small Cell Lung Cancer | Research | Study